Abstract
Multidrug-Resistant Tuberculosis in Child Successfully Treated with 9-Month Drug Regimen.
Highlights
To the Editor: Approximately 480,000 persons acquired multidrug-resistant tuberculosis (MDR TB) in 2013 (1)
Unlike the Bangladesh study (4), the Karakalpakstan study used moxifloxacin instead of gatifloxacin and included scheduled electrocardiograms (ECGs) and graded assessments of side effects to monitor for safety, including cardiac toxicity
We report the successful treatment of MDR TB in a child who received the 9-month drug regimen
Summary
To the Editor: Approximately 480,000 persons acquired multidrug-resistant tuberculosis (MDR TB) in 2013 (1). Along with the Ministry of Health of Uzbekistan, and in accordance with WHO advice (8), Médecins Sans Frontières investigated the efficacy, tolerability, and safety of the shortened regimen in Karakalpakstan, Uzbekistan (9), where rates of second-line drug resistance are high (1) and katG-mediated isoniazid resistance predominates. Limited data are available regarding use of 2 new TB drugs, bedaquiline and delamanid; the shortened regimen could represent the best opportunity to improve their outcomes and access to treatment.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
